The US Patent and Trademark Office (USPTO) recently issued an update to its procedures for interim Director Review (DR) of decisions by the Patent Trial and Appeal Board (PTAB),.
A trio of Federal Circuit judges on Tuesday seemed wary of Palo Alto Networks' claim that the U.S. Patent and Trademark Office director's blanket refusal to rehear petitions challenging Patent Trial and Appeal Board institution decisions undermines the U.S. Supreme Court's Arthrex decision.
A Federal Circuit panel weighed the latest installment in the ongoing Arthrex saga Wednesday, pressing the government on its argument that a longstanding U.S. Patent and Trademark Office directive authorizes Drew Hirshfeld, the interim leader of the agency, to implement the U.S. Supreme Court's Arthrex remedy.
While the nascent nonfungible token marketplace's intellectual property landscape was the hottest topic this year, Law360 guest experts also dug into the U.S. Supreme Court's Arthrex decision, how the West Texas "rocket docket" affects inter partes review, and a wide variety of statistical analyses concerning patent litigation and prosecution.
The Federal Circuit should hold off on deciding whether acting U.S. Patent and Trademark Office Director Drew Hirshfeld has the authority to review Patent Trial and Appeal Board decisions, the agency said Wednesday, saying any challenge to its procedures was still "premature."